Geode Capital Management, LLC Harpoon Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.6 - $1.41 $7,381 - $17,347	-12,303 Reduced 5.38%	216,431 $157,000
Q2 2022 Aug 12, 2022	SELL	$1.78 - $5.02 $299,853 - $845,654	-168,457 Reduced 42.41%	228,734 $436,000
Q1 2022 May 13, 2022	SELL	$3.54 - $8.08 $72,131 - $164,638	-20,376 Reduced 4.88%	397,191 $1.97 Million
Q4 2021 Feb 11, 2022	BUY	$5.69 - $7.83 $212,544 - $292,481	37,354 Added 9.82%	417,567 $3.15 Million
Q3 2021 Nov 12, 2021	BUY	$7.88 - $14.0 $222,617 - $395,514	28,251 Added 8.03%	380,213 $3 Million
Q2 2021 Aug 13, 2021	BUY	$13.81 - $23.25 $782,861 - $1.32 Million	56,688 Added 19.2%	351,962 $4.88 Million
Q1 2021 May 12, 2021	BUY	$17.65 - $24.16 $1.98 Million - $2.71 Million	112,333 Added 61.4%	295,274 $6.18 Million
Q4 2020 Feb 12, 2021	BUY	$12.83 - $17.84 $338,416 - $470,565	26,377 Added 16.85%	182,941 $3.04 Million
Q3 2020 Nov 13, 2020	BUY	$11.01 - $18.52 $284,993 - $479,390	25,885 Added 19.81%	156,564 $2.66 Million
Q2 2020 Aug 13, 2020	BUY	$11.11 - $24.72 $346,054 - $769,978	31,148 Added 31.29%	130,679 $2.17 Million
Q1 2020 May 14, 2020	BUY	$10.74 - $16.32 $129,996 - $197,537	12,104 Added 13.84%	99,531 $1.15 Million
Q4 2019 Feb 13, 2020	BUY	$12.94 - $20.58 $605,579 - $963,123	46,799 Added 115.19%	87,427 $1.29 Million
Q3 2019 Nov 12, 2019	BUY	$10.93 - $17.47 $59,830 - $95,630	5,474 Added 15.57%	40,628 $554,000
Q2 2019 Aug 14, 2019	BUY	$10.0 - $13.03 $234,450 - $305,488	23,445 Added 200.23%	35,154 $457,000
Q1 2019 May 14, 2019	BUY	$9.47 - $17.01 $110,884 - $199,170	11,709 New	11,709 $110,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.